ANIK — Anika Therapeutics, Inc.
—
Nasdaq ·
Health Care ·
Health Care Equipment & Supplies ·
CIK 898437 ·
Last close
$20.37
Market Cap
$272.61M
52W High
$22.88
52W Low
$8.67
ADV30
93,893
Next earnings
2026-11-04
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | Gross profit | Op income | Net income | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Jun 2026 | 32,610,000 | 21,244,000 | 2,954,000 | 3,309,000 | 183,474,000 | 38,412,000 | 46,192,000 |
| Mar 2026 | 29,612,000 | 18,997,000 | -5,488,000 | -5,056,000 | 179,387,000 | 41,020,000 | 45,486,000 |
| Dec 2025 | 30,615,000 | 19,179,000 | 646,000 | 292,000 | 190,270,000 | 57,481,000 | 46,805,000 |
| Sep 2025 | 27,817,000 | 15,584,000 | -3,233,000 | -2,329,000 | 189,437,000 | 57,990,000 | 42,632,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$5,977,000
Investing CF
$-4,053,000
Financing CF
$-16,340,000
CapEx
$-5,415,000
Dividends Paid
—
Buybacks
$-15,057,000
EPS Diluted TTM
$-0.27
As of
2026-08-02
Balance + Analyst (yfinance extras)
Retained Earnings
$59,040,000
Inventory
$28,565,000
Receivables
$29,062,000
ST Investments
—
EBIT TTM
$-5,121,000
Pretax Income TTM
$-2,913,000
Interest Exp TTM
—
Analysts
2
Yahoo Snapshot (yfinance, live)
Total Revenue
$120,654,000
EBITDA
$3,040,000
Free Cash Flow
$3,062,375
Enterprise Value
$266,006,672
Total Cash
$38,412,000
Total Debt
$25,250,000
Shares Out
13,382,966
Trailing EPS
$-0.23
Book Value
$10.26
ROE
-2.2%
ROA
-0.9%
Div Yield
—
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | Op income | Net income | Assets | Liabilities | Equity | Op cash flow |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 112,819,000 | -11,051,000 | -10,880,000 | 190,270,000 | 46,805,000 | 143,465,000 | 11,188,000 |
| Dec 2024 | 119,907,000 | -5,101,000 | -56,385,000 | 202,740,000 | 48,751,000 | 153,989,000 | 5,403,000 |
| Dec 2023 | 120,792,000 | 844,000 | -82,667,000 | 270,632,000 | 58,367,000 | 212,265,000 | -1,788,000 |
| Dec 2022 | 113,827,000 | 3,670,000 | -14,859,000 | 349,128,000 | 63,565,000 | 285,563,000 | 4,409,000 |
TTM Snapshot
Revenues TTM
—
NetIncome TTM
—
OpCashFlow TTM
—
Assets (Latest)
—
Forward EPS
$0.95
Max Pain — expiry 2026-12-18 (volume-derived — Yahoo OI feed degraded)
max pain strike: $20.00 · spot: $20.82 · call volume: 27 · put volume: 30
Expected Move to 2026-12-18:
±$2.90
(13.93%) —
implied range
$17.92 –
$23.72
· ATM straddle on $20.00 strike
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| OSUR | ORASURE TECHNOLOGIES INC | $271.05M | $3.93 | — |
| TLSI | TriSalus Life Sciences, Inc. | $267.23M | $4.34 | — |
| TMCI | TREACE MEDICAL CONCEPTS, INC. | $292.66M | $4.50 | — |
| INFU | InfuSystem Holdings, Inc | $253.15M | $12.71 | — |
| MOBI | Mobia Medical, Inc. | $301.62M | $9.06 | — |
News headlines (Yahoo Finance, 1h cache)
Is Anika Therapeutics (ANIK) Outperforming Other Medical Stocks This Year?
2026-09-25 12:40 · Yahoo
Merck's Remigromig Meets Main Goal in Diabetic Macular Edema Study
2026-09-25 14:19 · Yahoo
AMGN's Dazodalibep Meets Goal in Systemic Sjogren's Disease Study
2026-09-23 14:38 · Yahoo
NVS Gets Positive CHMP Opinion for Cosentyx for Another Indication
2026-09-21 15:57 · Yahoo
PBYI's Alisertib Combo Phase II Study in Small Cell Lung Cancer Begins
2026-09-18 14:48 · Yahoo
RCKT Aligns With FDA on Completing Phase II Study in Danon Disease
2026-09-16 14:56 · Yahoo
Immunocore Hits Enrollment Target in Kimmtrak Label Expansion Study
2026-09-15 15:22 · Yahoo
Roche Gets FDA Priority Tag for Enspryng in Rare Autoimmune Disorder
2026-09-10 15:42 · Yahoo
Novartis' Del-desiran Fails Late-Stage DM1 Study, Shares Fall
2026-09-09 18:47 · Yahoo
FDA Accepts & Gives Priority Review to Intellia's BLA for HAE Drug
2026-09-09 14:05 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.